High-profile groups have proposed population-scale testing as key to a safe reopening, but the test numbers they propose dwarf current and projected lab capacity.
A professor of pathology and laboratory medicine, Gregory Tsongalis has published a paper detailing his lab's work on SARS-CoV-2 testing and the challenges faced.
Driven by increased demand for SARS-CoV-2 assays and a return of routine testing, the rise suggests that the industry could be moving toward a recovery.
The system provides real-time data on SARS-CoV-2 testing availability across hundreds of hospital labs, helping providers get test orders filled more quickly.
The company is completing a study of its digital microscopy system which uses a computational approach that it said enables high-speed, high-resolution scanning.
Currently under development by a number of IVD firms, these protein tests offer quick turnaround, ease of use, and amenability to large scale production.
A number of labs have said that not only are they able to fulfill all current PCR test requests, but that they are operating at below capacity for these tests.
The company has identified progesterone metabolites linked to preterm birth and is looking to develop them for predicting risk of delivery prior to 32 weeks.
A lack of specificity in CMS guidelines combined with increased FDA scrutiny of LDTs could make it more difficult for labs to make changes to existing assays.
